RNS - Great News14 Apr 2020 13:30
As announced on 31 March 2020, the first patient was dosed in the Company's double-blind, placebo-controlled trial of SNG001 (the Company's wholly-owned inhaled formulation of interferon-beta-1a) in COVID-19 patients. The trial has now been labelled as an Urgent Public Health study by the National Institute for Health Research (NIHR). Further updates will be made in due course.